Every claim.
Cited.

Gastric pentadecapeptide with the most extensive preclinical tissue repair evidence base of any peptide in this category.

Synthetic thymosin β4 fragment regulating actin dynamics, cell migration, angiogenesis, and systemic tissue repair.

Endogenous copper-binding tripeptide that modulates over 4,000 human genes related to skin repair, collagen synthesis, and anti-aging.

ACTH(4-7) analog with human clinical trial data for stroke and cognition; potently upregulates BDNF and NGF.

Tuftsin-analog anxiolytic with human trials — anxiolytic effects without sedation, dependence, or withdrawal.

Soviet-era actoprotector combining dopaminergic and anxiolytic effects without classic stimulant side effects.

FDA-approved recombinant growth hormone with extensive clinical evidence and a well-characterized side effect profile.

IGFBP-resistant IGF-1 analog with dramatically extended half-life — and a serious cardiac hypertrophy risk that is underreported.

GHRH analog with DAC albumin-binding modification extending half-life to ~8 days for sustained GH and IGF-1 elevation.

Selective GHRP with minimal cortisol and prolactin elevation — the cleanest GH secretagogue pharmacological profile.

FDA-approved GLP-1 agonist with landmark RCT evidence for weight loss (~15% body weight) and cardiovascular risk reduction.

First-in-class dual GIP/GLP-1 agonist — superior weight loss to semaglutide, up to 22.5% body weight reduction in trials.

Triple GIP/GLP-1/glucagon agonist showing 24.2% mean weight reduction in Phase 2 — the largest ever reported for a pharmacological agent.

Synthetic pineal tetrapeptide studied for telomerase activation, melatonin restoration, and anti-aging effects in animal models.

The only oral GH secretagogue with human RCT data — pulsatile GH preservation, documented sleep benefit, and documented glucose dysregulation.

FDA-approved GHRH analog for HIV lipodystrophy — uniquely selective for visceral fat reduction without affecting subcutaneous fat.

The first centrally-acting FDA-approved treatment for female sexual dysfunction — works on desire pathways, not vascular mechanisms.

Non-selective melanocortin agonist with seriously underreported risks including renal infarction, rhabdomyolysis, and eruptive nevi.

Selective MC1R agonist — afamelanotide (Scenesse) is FDA-approved for erythropoietic protoporphyria, the first approved melanocortin drug.

Neuropeptide mixture with the strongest clinical evidence base in this category — multiple RCTs and meta-analyses in stroke, TBI, and Alzheimer's.

HGF/MET signaling activator with potent pro-cognitive effects in rodent models — but significant evidence integrity issues.

Endogenous thymic immunomodulatory peptide with compelling evidence in cancer immunotherapy and hepatocellular carcinoma survival.

C-terminal α-MSH tripeptide that blocks NF-κB and MAPK inflammation via PepT1-mediated uptake — no melanocortin receptor required.

Mitochondrial-encoded exercise-induced peptide with a unique folate-AICAR-AMPK mechanism and longevity genetics link in Japanese centenarians.

Competing peptide that blocks the CXXC5-Dishevelled interaction to reactivate Wnt/β-catenin hair follicle growth signaling — outperforms minoxidil in mice.